June 07, 2026
5 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Weekly survodutide confers dual benefits for obesity, metabolic liver disease
NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic dysfunction-associated steatotic liver disease.Researchers reported new data from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials of survodutide (Boehringer Ingelheim/Zealand Pharma) at the American Diabetes Association Scientific
1,638 words~7 min read
